Biologics are drugs produced from living organisms or containing specific components derived from living organisms. Biosimilars are products similar to biologics in efficacy, composition, and mechanism of action. Biosimilars are considered derivatives of biologics. They are manufactured after the reference product’s (Biologic) patent license expires.

In this post, we will examine multiple biologics and analyze spending trends for the biosimilars in Medicare Part D. Our primary focus is overall spending, claims trends, and cost per prescription from 2019 to 2023.

READ MORE